title: Prevention and treatment of alloantibody-mediated kidney transplant rejection.
abstract: Antibody-mediated rejection (AMR), which is commonly caused by preformed and/or de novo HLA alloantibodies, has evolved as a leading cause of early and late kidney allograft injury. In recent years, effective treatment strategies have been established to counteract the deleterious effects of humoral alloreactivity. One major therapeutic challenge is the barrier of a positive pretransplant lymphocytotoxic crossmatch. Several apheresis- and/or IVIG-based protocols have been shown to enable successful crossmatch conversion, including a strategy of peritransplant immunoadsorption for rapid crossmatch conversion immediately before deceased donor transplantation. While such protocols may increase transplant rates and allow for acceptable graft survival, at least in the short-term, it has become evident that, despite intense treatment, many patients still experience clinical or subclinical AMR. This reinforces the need for innovative strategies, such as complementary allocation programs to improve transplant outcomes. For acute AMR, various studies have suggested efficiency of plasmapheresis- or immunoadsorption-based protocols. There is, however, no established treatment for chronic AMR and the development of strategies to reverse or at least halt chronic active rejection remains a big challenge. Major improvements can be expected from studies evaluating innovative therapeutic concepts, such as proteasome inhibition or complement blocking agents.
authors.affiliation: Department of Medicine III, Medical University Vienna, Vienna, Austria.
authors.forename: Gregor
authors.initials: G
authors.lastname: Bartel
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Schwaiger
authors.forename: Georg A
authors.initials: GA
authors.lastname: Böhmig
mesh_terms: D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D006680:HLA Antigens / Q000097:blood; D006650:Histocompatibility Testing; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D007163:Immunosorbent Techniques; D007518:Isoantibodies / Q000097:blood* / Q000302:isolation & purification; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology*; D010956:Plasmapheresis; D061988:Proteasome Inhibitors; D014019:Tissue Donors
chemical_list: D000961:Antilymphocyte Serum; D051056:Complement Inactivating Agents; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies; D061988:Proteasome Inhibitors